Podcasts about syneos health

What are the signals today that will define the future of oncology treatment tomorrow?The Syneos Health Podcast: Early Signals brings together leaders across biopharma, healthcare, academia and technology to explore the innovations reshaping drug development in oncology. Hosted by experts across Syneos Health, including Wael Harb, MD, Head of Research and Development and Scientific Strategy in oncology, each episode captures candid conversations about emerging science, evolving market dynamics and the trends poised to influence the future of patient care.Tune in for timely perspectives on what's next—and what it means for the oncology industry, its stakeholders and most importantly its patients.Subscribe to The Syneos Health Podcast: Early Signals  for new episodes. If there's a topic you'd like us to explore, send us a message at podcasts@syneoshealth.com. For more actionable, future-focused life sciences insights, visit the Syneos Health Insights Hub. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us!  We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

In this episode of the Site Realities series, Tammy D'Lugin-Monroe continues her conversation with Przemyslaw Wziatek, Country Head for Poland and Ukraine within Clinical Operations at Syneos Health, exploring how sites navigate the complexity of working within large CRO organizations. Together, they discuss the importance of clear communication pathways, operational ownership and timely escalation processes in building strong site partnerships. From reducing communication noise to improving site launch meetings and helping sites quickly connect with the right support teams, the conversation highlights practical ways CROs can create a more seamless and supportive site experience.Listen in as they share perspectives on how thoughtful communication, clarity and collaboration can strengthen trust and improve study execution at scale.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us!  We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

In this episode of the Site Realities series, Tammy D'Lugin-Monroe sits down with Przemeslaw Wziatek, Country Head for Poland and Ukraine within Clinical Operations at Syneos Health, to explore how relationships between Clinical Research Associates (CRAs) and Clinical Sites are evolving in today's increasingly complex research environment. As competition for high-performing sites intensifies, strong partnerships have become more important than ever. Tammy and Przemeslaw discuss what sites truly expect from CRO partners, why the CRA role has evolved beyond monitoring into that of an ambassador and problem solver, and how trust is built through responsive, thoughtful communication. Together, they examine the realities sites face every day, from balancing patient care alongside multiple studies to navigating increasing operational complexity and technology demands. The conversation also explores how CROs can better align with site priorities, reduce communication friction and create stronger long-term partnerships that ultimately support study success and improve the patient experience.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us!  We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

In this episode of the Syneos Health Podcast: Site Realities series, host Tammy D'Lugin-Monroe and Audra Holleman, Head, Country Operations, Americas at Syneos Health explore the evolving role of the clinical research associate (CRA)—and why it matters more than ever. From shifting expectations around site relationships to the growing impact of technology and AI, the conversation highlights how CRAs are moving beyond transactional monitoring to become trusted partners, problem solvers and scientific advisors. Together, they unpack what sites and customers value most—responsiveness, continuity and deep expertise—and how an outcomes-based approach is reshaping CRA success. The episode also looks ahead, examining how innovation is freeing CRAs to focus on what drives real impact: strengthening site partnerships, improving patient experiences and accelerating study delivery.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us!  We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Commercialization decisions are shaping success earlier than ever in the product lifecycle, from value and access to launch strategy, deployment and stakeholder engagement. Conversations on Commercialization, a new spinoff of the Syneos Health Podcast, explores what this shift means for biopharma companies and what it takes to compete in a rapidly evolving market. Led by Tyler Cowan, Commercial Vice President at Syneos Health, and joined by a bench of expert co-hosts, the podcast brings together industry leaders to explore the trends, decisions and evolving commercial models defining success today.Subscribe to The Syneos Health Podcast: Conversations on Commercialization so you never miss an episode. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us!  We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

In this episode of the Syneos Health Podcast: Site Realities series, Tammy D'Lugin-Monroe, Head of Trial Enablement Solutions at Syneos Health, sits down with Mimi Fenton, MPH, PhD, CEO of Cedar Health Research, to explore what it truly means to operate on the front lines of clinical research. Drawing on her experience across pharma, CRO and site leadership, Mimi offers a candid view into the operational, financial and human realities that shape today's clinical trial landscape. The conversation highlights the growing disconnect between protocol design and real-world execution—and how sponsors and CROs can close that gap by engaging sites earlier, simplifying technology integration and prioritizing patient-centered approaches. Mimi also underscores the critical role of trust, emphasizing that sites serve as the face of the sponsor within communities and are essential to improving access, diversity and retention in clinical trials. From the burden of fragmented technology to the importance of long-term partnerships over transactional relationships, this episode offers practical insights on how the industry can better collaborate to accelerate trial delivery and improve outcomes for patients.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us!  We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Recorded on the heels of SXSW 2026, this MM+M x GSW podcast explores the cultural, technological and creative signals shaping the future of health marketing. Jennifer Batey, EVP of integrated strategy, and Bryan Roman, EVP and experience director at GSW, powered by Syneos Health, unpack the biggest themes emerging from Austin, from the evolving role of AI and immersive brand experiences to the growing importance of trust, community and creator-driven influence.  Moving beyond the buzzwords, the conversation focuses on what SXSW truly means for pharma marketers today. What cultural shifts should health brands be paying attention to? How are audience expectations changing? And how can regulated industries embrace innovation without losing authenticity? With a practical lens, Batey and Roman translate inspiration into action, offering clear takeaways for CMOs and brand leaders looking to stay ahead of where culture, technology and healthcare intersect.  Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What makes patient voice sessions the most impactful part of every SCRS summit? Jade Tuttle from Syneos Health breaks down what she learned from featuring patients at four summits in 2025. The recurring theme? There are still massive gaps in our systems, but sites that adapt proactively and deliver emotionally intelligent trials create transformative patient experiences. Jade shares standout stories, explains why regulatory bodies are increasingly mandating patient-centric practices, and reveals the measurable business case for patient-informed trials. She challenges the industry to move beyond reactive approaches and partner with patient advocacy organizations early in trial design. Learn how to turn "patient-centricity" from a buzzword into real, tangible practice. 

In this episode, Lynn Hamilton speaks with Stuart Goodall, Senior Vice President at Syneos Health, about how regulatory functions are evolving in response to growing complexity, accelerating timelines and emerging technologies. With more than 35 years of global experience, Stuart offers an unfiltered perspective on what regulatory and medical writing teams need to succeed today—and how to scale smartly for what's next. Topics explored include:·      The shift from information advantage to decision advantage in regulatory intelligence·      How AI is changing—not replacing—medical writing and regulatory operations·      What sponsors need to consider when building scalable, tech-enabled models·      Why FSP is no longer just transactional and how strategic partnerships are redefining value·      Why storytelling and judgment remain irreplaceable in an automated world Whether you're exploring your next medical writing solution or rethinking regulatory infrastructure, this conversation offers grounded insights with a forward-looking lens.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this forward-looking episode, Lynn Hamilton sits down with Bret Couturier, Executive Director, FSP 360 at Syneos Health, to explore how sponsors can shift from incremental improvements to intentional design when it comes to site experience. With a career spanning frontline monitoring to strategic FSP leadership, Bret offers practical insights into what's working, and what's holding teams back. Key themes include:Why the CRA role isn't disappearing, but rather evolving with AI and data-driven toolsThe importance of designing from the site's perspective, not just for internal efficiencyHow functional service provider (FSP) models can go beyond staffing to drive systemic improvementSimple but powerful steps sponsors can take now to reduce burden and build stronger site relationshipsWhat it means to move from reactive fixes to strategic collaboration, and why the time is now If you're rethinking site engagement, functional models or the next phase of FSP delivery, this conversation offers both strategic clarity and real-world takeaways.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode of the Functionally Speaking series, host Lynn Hamilton speaks with Carol Aliyar, Executive Vice President and Global Head of Safety and Pharmacovigilance (PV) at Syneos Health, about the transformation of PV from a highly regulated, task-oriented function into a more strategic and technology-enabled discipline. With over 30 years in the industry and a career that spans commercial, clinical and safety roles, Carol brings a rare full-spectrum perspective. Listeners will gain insight into:How PV is shifting from transactional taskwork to strategic lifecycle integrationWhat AI and automation really mean for safety operations and talent needsThe enduring importance of human judgment, especially in the age of AI agentsWhy functional service provider (FSP) models are now resonating in PVHow consistency, flexibility and subject matter depth strengthen long-term partnerships Whether you're expanding your PV model, exploring AI adoption or rethinking how functional teams deliver value, this conversation offers real-world perspective and practical foresight.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

What does it take to run a truly effective Functional Service Provider (FSP) model in today's biopharma landscape? From harmonizing global teams to embedding innovation into daily delivery, FSP engagement is more than a resourcing solution — it's about strategic collaboration and approaches that accelerate delivery. The Syneos Health Podcast: Functionally Speaking series explores the nuances that make these models work. In this episode of the Functionally Speaking series, host Lynn Hamilton sits down with Wayne Wise, Vice President of Clinical Operations at Syneos Health, to explore the real-world shifts happening in large pharma partnerships. With nearly two decades at the company and deep cross-functional experience, Wayne shares how agility, strategic governance and trust-based team leadership are reshaping FSP delivery models. From evolving CRA roles and co-created governance to the increasing use of AI, Wayne offers a firsthand look at how functional teams are adapting in real time to operational and strategic shifts across the industry.  You will walk away with insights on:Moving beyond transactional models to strategic, insight-driven partnershipsBuilding agile teams that thrive amid complexityTransforming governance to focus on action, not just KPIsHow the CRA role is evolving with tech-enabled site engagementWhat sponsors can do to unlock value through co-creationThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

What does it take to run a truly effective Functional Service Provider (FSP) model in today's biopharma landscape? From harmonizing global teams to embedding innovation into daily delivery, FSP engagement is more than a resourcing solution — it's about strategic collaboration and approaches that accelerate delivery. The Syneos Health Podcast: Functionally Speaking series explores the nuances that make these models work.  In this episode of Functionally Speaking, host Lynn Hamilton welcomes Matt Lawton, Executive Director of FSP Delivery at Syneos Health, to explore the unique challenges and opportunities facing small-to-mid-size (SMID) biopharma sponsors. Often operating with leaner resources and evolving pipelines, these companies require partners who can flex with their journey—not just deliver headcount.With over 15 years of experience guiding functional partnerships, Matt offers grounded insights on how to build trust-based FSP models tailored to each sponsor's origin, stage and future goals.  Listeners will gain a practical understanding of:What truly defines the SMID segment—and why it's a space of rapid innovationHow functional support needs vary widely across early- to mid-stage sponsorsThe critical role of adaptability in both delivery teams and partnership modelsWhy strong cultural fit and team integration matter more in SMID engagementsWhen to start considering FSP—and how a conversation, not a contract, is often the best first stepIf you're working in or with an emerging biopharma organization, this episode offers a valuable look into how functional partnerships can evolve to meet you where you are—and grow with you.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

What if protein degradation could address neurodegenerative diseases, not just cancer? In this episode, Dr. Angela Cacace, CSO at Arvinas, speaks with Dr. Talar Hopyan, Global Head of CST at Syneos Health, about how the company is advancing a degrader targeting LRRK2 in Parkinson's disease and why early-stage signals in healthy volunteers are raising new possibilities for CNS care. They discuss how Arvinas is engineering blood-brain barrier-penetrant molecules, the translational challenges in neurodegeneration and what's required to move from platform to patient. What you'll learn: How Arvinas is expanding targeted protein degradation into neurology Why LRRK2 degradation is a promising approach for Parkinson's disease What it takes to translate platform innovation into measurable clinical outcomes The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Hosted by MM+M, this episode brings together Cathy Eschenbach, SVP, group account director of Genicos, powered by Syneos Health, and John Kirk, SVP, group creative director of Genicos, powered by Syneos Health, for a conversation about the agency's new positioning and its rallying cry:“It's GO Time.”The discussion explores how Genicos helps small and midsize biopharma (SMID) companies bring breakthrough therapies to market — faster, smarter and with purpose. Eschenbach and Kirk unpack what “GO” means as an ethos, not just a tagline; why emerging biotechs are their ideal partners; and how Genicos blends scientific depth and creative firepower to accelerate launches and impact patient outcomes.  Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Now in its second season, this exclusive CNS Summit podcast series features biopharma leaders sharing bold ideas, breakthrough innovations and what it takes to move smarter and faster for patients. How is a mid-sized, family-owned company scaling with impact in specialty neurology? Stefan König, CEO of Merz Therapeutics, joins guest host Andy Moniz, VP of Therapeutic Strategy and Innovation at Syneos Health at the 2025 CNS Summit. Together, they explore what it takes to lead through volatility, invest globally and grow with intention, all while upholding culture and delivering with purpose. In this episode: How Merz is leveraging global capital to expand its neurology pipeline What today's market volatility reveals about opportunity Why “balanced disruption” matters for scaling innovation The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Now in its second season, this exclusive CNS Summit podcast series features biopharma leaders sharing bold ideas, breakthrough innovations and what it takes to move smarter and faster for patients. Compass Pathways CEO Kabir Nath joins host, Dr. Alex Wise, Global Head of Neuroscience at Syneos Health, to discuss the clinical promise of psychedelics and what's next for psychiatric innovation.  What you'll learn: What's driving the momentum behind psilocybin therapy Why investor confidence is growing in mental health biotech How biopharma can better communicate the value of innovation Kabir's message to next-gen leaders in science and strategy The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Hosted by MM+M, this episode brings together Oliver Nelson, managing director at Evolvics, powered by Syneos Health, and Chris Tuleya, EVP of media at Evolvics, for a candid conversation on why most brands are getting media reporting wrong. Too often, marketers focus on vanity metrics such as clicks and impressions, numbers that look good on a dashboard but fail to connect with real business outcomes. Nelson and Tuleya will unpack why traditional reporting falls short, how interactive, real-time approaches are reshaping decision-making and what it means to go beyond dashboards and PowerPoints to create truly integrated performance intelligence.   Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A new limited series of the Syneos Health Podcast, Conversations on Commercialization unpacks how biopharma leaders are rewriting the commercial playbook, redefining what it takes to succeed.  In this episode, recorded at Fierce Pharma Week 2025, Tyler Cowan, VP Commercial at Syneos Health, joins Hruta Shah, Senior Engagement Manager for Syneos Health Consulting, to break down the high-stakes race in obesity treatment and the commercial boom around GLP-1 therapies.  You'll hear: What emerging launch strategies look like in a crowded, competitive pipeline and how success is being redefined How GLP-1s are accelerating a shift in stakeholder dynamics, including telehealth, large employers and direct-to-patient platforms Why traditional DTC advertising is evolving and how informed patients are influencing brand messaging The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

A new limited series of the Syneos Health Podcast, Conversations on Commercialization unpacks how biopharma leaders are rewriting the commercial playbook, redefining what it takes to succeed.  Recorded at Fierce Pharma Week 2025, the series begins with a two-part conversation with Mark Bard, co-founder of the Digital Health Coalition. In this episode, Bard joins host Tyler Cowan, VP, Commercial at Syneos Health to unpack how the pandemic reshaped provider expectations and the continued impact on commercial teams. From feedback loops to content fatigue, to the myth of multichannel mastery, they break down what it takes to engage HCPs on their terms. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode, we explore the story behind the Empathy Engine — Syneos Health Communications' groundbreaking consumer data hub that's transforming the way healthcare brands connect with people. Built at the intersection of behavioral science and emotional insight, the Empathy Engine reveals the "why" behind health decisions. Hear from the minds behind the Engine and learn how it's helping marketers deliver stories that matter and drive positive change — before audiences even know they need to hear them. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Dear Art Producer' host Heather Elder sits down with Hannah Wolfert, a Senior Content Producer at Syneos Health, and Kim Roemer, a Content Production Business Manager, who have collaborated for nearly 17 years. The discussion delves into their unique career paths, spanning from art history classes to diverse roles in content production and business management. They reflect on their early professional encounters, the importance of industry relationships, and the evolving landscape marked by AI and integrated media projects. The conversation also touches on the complexities of licensing, the relevance of advances in production, and the integral role of business affairs in streamlining workflow. Tune in for insights on staying adaptable in a rapidly changing industry and the blend of creative and administrative skills required to thrive.   In an industry where the rules are always changing, it's helpful to hear from those on the front lines. Heather Elder is the visionary behind NotesFromARepsJournal.com; visit HeatherElder.com for industry updates, stunning photography and video, and the artists behind the work.   More about our guests: Connect with Hannah Wolfert: https://www.linkedin.com/in/hwolfert/  Connect with Kim Roemer: https://www.linkedin.com/in/kim-roemer-2026a570/    More about your host: Heather Elder's Bio Heather Elder's Blog Heather Elder on Instagram Heather Elder on Twitter Heather Elder on LinkedIn Heather Elder on Facebook

What Cannes taught us about health creativity in 2025.Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register!    AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket!    Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

In this special edition of the Syneos Health Podcast recorded from the floor of Asembia's AXS25 Summit, host Michael Sarshad sits down with Kim Plesnarski, SVP of Market Access and Patient Support Services at Syneos Health and Kelly Carter, AVP of Patient Support at Amgen, to unpack the evolving landscape of patient support. The discussion explores the blurring lines between general and specialty medicine, the growing administrative burden on providers and the need to embed seamless, tech-enabled support into the healthcare journey. The trio dives into the role of Field Reimbursement Managers (FRMs), payer challenges, affordability barriers and how AI and automation are beginning to transform operations—from personalized patient education to proactive intervention. If you're interested in how manufacturers can shift from reactive to proactive models and scale personalized support in an increasingly complex environment, this episode is a must-listen.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this special edition of the Syneos Health Podcast recorded from the floor of Asembia's AXS25 Summit, host Michael Sarshad speaks with Kim Plesnarski, SVP of Market Access and Patient Support Services at Syneos Health and Greg Morris, Chief Strategy Officer at CareMetx. They explore the latest trends shaping patient support services—from the surge of AI-powered solutions to the shift toward hybrid hub models. The conversation dives into the challenges of reactive support programs, the need for continual innovation and the nuanced debate between insourcing and outsourcing. With practical insights and real-world examples, Kim and Greg share strategies for building scalable, tech-forward patient service models that meet the evolving demands of both patients and providers.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

We continue our Project Optimus series with a focus on clinical pharmacology—a foundational element in redefining dose optimization in oncology drug development. Dr. Wael Harb is joined by Pierre-Olivier Tremblay, Vice President of Clinical Pharmacology at Syneos Health, to discuss how model-informed strategies, exposure-response analysis and biomarkers are transforming early phase trials. They examine how tools like PK/PD modeling and tumor dynamics simulations enable a shift from traditional maximum tolerated dose approaches to more patient-centric dosing strategies, and explore how AI, data sharing and regulatory innovation are shaping the future of precision oncology.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Hosted by Drew Beck, Head of Strategy, Growth and Innovation for Syneos Health Learning Solutions, this limited series dives into the breakthrough trends redefining health in 2025 and beyond. From bold moves in R&D and medical affairs to next-gen trial design, product launch strategies and the future of healthcare communications, each episode connects you with the minds driving real change. Big ideas. Real-world impact. In this episode, Drew dives into launch excellence in 2025 with Syneos Health experts Larry Dollar, VP of Medical Affairs, and Michael Sarshad, Managing Director, Consulting. Together, they unpack how strategic spending, agile planning and early investment in medical resources are driving launch success. They explore the rise of new medical affairs roles using the transformative impact of AI on clinical trials, and the evolving needs of field teams. The discussion also highlights how innovations like machine learning–driven physician segmentation are helping companies identify new clinical trial sites faster and more precisely. Whether you're with an emerging biotech or a large pharma company, you'll get key insights on collaboration, creativity and why the year leading up to launch is more critical than ever. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode, leaders from Salix Pharmaceuticals and Syneos Health Communications share their real-world journeys to becoming truly "omni-ready" — from overcoming data roadblocks to rethinking ROI and scaling strategic pilots. Hear how cross-functional alignment, mindset shifts and bold decisions shaped their omnichannel success and get practical insights for navigating your own transformation. Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

2025 Health Trends meets The Syneos Health Podcast for a limited series exploring how Trends come alive in the life sciences industry with host Drew Beck, Head of Strategy, Growth and Innovation for Syneos Health Learning Solutions. Syneos Health experts Brian Carver, Executive Director of Therapeutic Strategy and Innovation, Rare Disease Consortium, Vik Chawla, Managing Director, Syneos Health Consulting and Katya Magonova, Managing Director, Syneos Health Consulting explore the role of AI in rare disease drug development, diagnosis and treatment. They share how AI is accelerating R&D, improving patient identification and enhancing clinical trials. The discussion also highlights investment trends in AI within the healthcare sector, the emergence of AI-first companies and the ongoing challenges and opportunities of integrating AI into life sciences, underpinned with data from our 2025 Dealmakers' Intentions Survey. Emphasizing the importance of understanding AI's applications and implications, host Drew Beck has a special call to action for the industry to harness AI's power in drug development and commercialization today. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The biopharma market is booming—but not without turbulence. In this kickoff episode of our special podcast series in collaboration with Asembia, hosts Michael Sarshad, Managing Director, Commercial Advisory, Syneos Health and Sara Rubin, Senior Vice President, Market Access Strategy at Spherico, a Syneos Health company, unpack the dynamic forces reshaping how therapies reach patients. Recorded ahead of Asembia's AXS25 Specialty Pharmacy Summit, they dive into the impact of tariffs, the power of AI in streamlining patient support, the ripple effects of the Inflation Reduction Act and how digital transformation is changing the way manufacturers engage population health decision-makers. Tune in for expert insights, preview topics for this year's summit, and discover how the industry is responding to rising complexity with strategic innovation.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Send us a textIn this episode of the Life Science Success Podcast my guest is Matt Veatch, President & COO and Co-Founder of Navidence, Inc., a SaaS company advancing the use of Computable Operational Definitions for real-world data in clinical trials and evidence generation. With over 30 years of experience in biopharmaceutical and medical device development, Matt brings extensive leadership expertise from roles at Syneos Health, Quintiles, and his own consulting practice.00:00 Introduction to Life Science Success Podcast00:30 Meet Matt Veatch: President and COO of Navidence01:22 Matt's Journey in the Life Science Industry05:49 Entrepreneurial Ventures and Consulting06:54 The Birth of Navidence17:26 Navidence's Mission and Impact27:25 Innovative Projects and Partnerships30:58 Matt's Podcast and Personal Insights35:13 Leadership Advice and Inspirations38:55 Concerns and Future Excitements46:33 Conclusion and Farewell

Shauna Keough, President of U.S. Public Relations at Syneos Health, shares how she applies behavioral science to build stronger client relationships. She emphasizes the importance of understanding key factors like risk and work-life balance to gain deeper insights into client mindsets. Shauna also explains how she leverages these insights to strengthen her partnerships and drive success. Learn more about D S Simon Media.

As regulatory expectations evolve under the FDA's Project Optimus oncology dosing initiative, biostatistics is emerging as a central pillar in designing and executing trials that move beyond the traditional maximum tolerated dose (MTD) approach.In this fourth episode of our Project Optimus series, host Dr. Wael Harb is joined by biostatistics expert X.Q Xue, PhD, Vice President and Global Head, Biostatistics at Syneos Health to explore how statistical science is transforming dose optimization in oncology drug development. Dr. Xue discusses the limitations of legacy 3+3 dose-escalation designs and introduces innovative alternatives, including Bayesian modeling, adaptive trial strategies and randomized parallel dose-response studies, which support more precise dose selection and can ultimately improve patient outcomes and trial efficiency.Together, Drs. Harb and Xue examine how smaller biotech companies can overcome barriers to implementation, the role of simulation and AI in trial planning and how a biostatistics-driven approach may increase the likelihood of late-phase success, reduce post-marketing adjustments and support faster regulatory approvals.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Guided by complex regulatory and trademark requirements, brand teams have often had to sacrifice creativity for compliance. Traditional naming methods, unchanged for decades, alongside crowded markets have led to shrinking white space, high attrition rates and weakened brand strategies. In this episode, Joe Daley, president of Addison Whitney, powered by Syneos Health, explores how Ari, the industry's first AI-driven naming platform, is breaking through these barriers. By integrating real-time regulatory and trademark screening, Ari expands creative white space within set guardrails, empowering deeper strategic exploration and compliance like never before possible — reducing risk while increasing creativity. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

In this episode of The Syneos Health Podcast, we continue our exploration of Project Optimus and the evolution of dose optimization in oncology drug development. Following our discussion on regulatory expectations in the previous episode, we now turn to the operational challenges and strategies required to implement optimized dosing in real-world settings.Host Dr. Wael Harb is joined by Patrick Melvin, Vice President, Oncology & Hematology and Global Head, Novel and Emerging Therapies at Syneos Health, to discuss the complexities of operationalizing Project Optimus. Together, they examine how drug developers, investigator sites and patients are affected by these changes, the role of adaptive study designs, and how AI-driven technologies and digital health innovations are helping to streamline dose optimization.Tune in to gain valuable insights into the future of precision dosing and the long-term benefits of this industry shift, from improving patient outcomes to enhancing drug development efficiency.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Ever had a work dilemma so awkward you'd rather fake a panic attack than ask your boss? Well, we've got you covered. This week, our expert agony aunts tackle your toughest questions, including:

What separates top-performing medical sales reps from the rest?  It's not just talent; it's elite training. Amy Harrington, VP of Clinical Training, reveals how the right approach to learning can make or break your success in this industry. Inside this episode: How Amy went from surgical tech to nurse to top-tier medical sales leader Why sales training isn't optional—it's the secret weapon for dominating the field The overlooked power of personalized learning in high-stakes industries How startups shaped her ability to adapt, innovate, and build winning teams Whether you aim to break in, level up, or reinvent your career, this episode delivers the insider playbook for thriving in medical sales. Meet the guest:  Amy Harrington is the Vice President of Clinical Training and Practice Development at R2 Technologies, Inc., where she leads the company's clinical education and advancement strategies. With over a decade of experience in the aesthetic and medical technology industries, Amy is known for designing innovative training programs that equip sales teams to sell confidently through science and knowledge. Since joining R2 in 2021, Amy has been a driving force behind the company'scompany's growth and innovation. Her strategic leadership—first as Director of Clinical Development & Education, then as Senior Director of Clinical Development, and now as VP of Practice Development—has been instrumental in establishing the R2 brand within clinical practices. Her contributions reflect a deep commitment to advancing the field of aesthetics through education and collaboration. Before R2, Amy held impactful leadership roles at Syneos Health, Obagi, and Solta Medical, where she developed and implemented transformative clinical and sales training programs. Beginning her career as a Registered Nurse in the operating room, she gained invaluable hands-on experience that continues to inform her practical and patient-centered approach to clinical education. Amy's academic background includes a dual bachelor's Degree in nursing and biology from the University of Maine, as well as an associate's Degree in criminalistics. She further enhanced her expertise in curriculum development with an instructional design certification from the Association of Talent Development. Outside of her professional endeavors, Amy is a wellness enthusiast who enjoys yoga, rowing, and exploring Maine's landscapes. A proud dog mom, she embraces an active outdoor lifestyle while balancing her passion for transforming clinical education with her love for the outdoors.  Connect with her:  LinkedIn Instagram

In this episode, we welcome Dr. Rishi Kakar, Chief Scientific Officer and Medical Director at Segal Trials. Host Andy Moniz, Vice President, Therapeutic Strategy & Innovation at Syneos Health, sits down with Dr. Kakar to explore his inspiring journey from a 15-year-old immigrant discovering neuroscience in a Queens library to becoming a leader in clinical research and innovation.Dr. Kakar shares the personal moments that shaped his passion for psychiatry, the pivotal experiences that drove his commitment to understanding the drug development process, and how Segal Trials has remained at the forefront of clinical research. From pioneering psychedelic trials to building innovative quality dashboards, Dr. Kakar offers insights into the future of patient-centric clinical trials, workforce transformation, and the integration of emerging technologies.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode of the Syneos Health Podcast, series host Dr. Wael Harb, Vice President of Medical Management at Syneos Health, continues the exploration of FDA's groundbreaking Project Optimus and its profound implications for oncology drug development. He is joined by Zohra Lomri, Executive Director, Regulatory Affairs at Syneos Health, to discuss how this initiative is transforming dose optimization strategies and reshaping the clinical trial landscape.The conversation delves into the FDA's emphasis on balancing efficacy and tolerability, the shift away from maximum tolerated doses, and the integration of patient-reported outcomes. Zohra provides valuable insights on the regulatory expectations for dose-ranging studies, the importance of leveraging non-clinical data, and the role of pharmacokinetics (PK) and pharmacodynamics (PD) modeling in optimizing trial designs.Whether you're in oncology drug development or interested in regulatory innovation, this episode offers actionable advice and a glimpse into the future of patient-focused drug development.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Georgie Kovacs is a seasoned professional with over two decades of healthcare expertise, having contributed to industry giants like Pfizer, Syneos Health, IQVIA, and Bristol-Myers Squibb. She launched Fempower Health in 2020, a pioneering platform that empowers women with evidence-based insights and support. Collaborating with top experts, Georgie is dedicated to redefining the narrative surrounding women's health, ensuring every woman has the knowledge and resources to thrive and make informed decisions about their health. In this episode, Georgie opens up about her personal and professional story, shaped by her roots as the daughter of Hungarian immigrants and the challenges of forging her path in the healthcare industry. Discover her unique approach to overcoming obstacles, her mental strength cultivated through long-distance running, and the lessons she's learned about breaking down big problems into manageable steps. Tune in for a conversation filled with vulnerability, grit, and actionable insights that will leave you inspired to tackle your own challenges head-on. Don't miss Georgie's powerful message about persistence, self-discovery, and creating a meaningful impact in the world. Website- https://www.fempower-health.com/ Social Media Links/Handles- https://www.instagram.com/fempowerhealth https://www.youtube.com/@fempowerhealth

Recorded from the 15th annual CNS Summit, Andy Moniz, Vice President of Therapeutic Strategy Innovation at Syneos Health, sits down with Jane Metcalfe, Board Chair of the Human Immunome Project, to discuss the transformative potential of immunology in medicine. Jane shares her inspiring journey into this groundbreaking field, highlighting how advanced biological measurements, machine learning, and personalized immune profiling are reshaping drug development, clinical practice, and medical education.From the immune system's role in diseases like Alzheimer's and cancer to the need for diverse clinical trials, this conversation explores the dynamic intersection of science, technology, and humanity.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Join host Andy Moniz, Vice President of Therapeutic Strategy Innovation at Syneos Health, as he sits down with Dr. David Brown from Community Clinical Research in Austin, Texas, for a compelling conversation recorded from the floor of CNS Summit. In this episode, Dr. Brown shares his journey into psychiatry, inspired by his experiences in medical school and his personal connection to mental health.The discussion delves into the transformative impact of clinical trials, the advancements in schizophrenia research, and the potential for a new era in personalized psychiatry driven by genetic insights and AI. Dr. Brown reflects on the challenges of stigma, the progress in neuroscience, and his hopes for the industry in the next five years, including bridging gaps between academia and pharma and inspiring the next generation of researchers.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode, recorded from the floor of the CNS Summit, host Andy Moniz, Vice President of Therapeutic Strategy and Innovation at Syneos Health, sits down with Cristina Duran, CEO of Evinova, to discuss her transformative journey in life sciences and the future of patient-centric innovation in healthcare.Cristina shares insights from her experience leading R&D transformation at AstraZeneca, where she pioneered patient-centric approaches to clinical trials. She discusses how Evinova is driving industry-wide change by creating integrated, scalable solutions that prioritize patient needs while delivering faster, more efficient outcomes for life sciences—emphasizing the importance of collaboration, learning from failures, and connecting across the sector to accelerate progress.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this special series of the Syneos Health Podcast, we celebrate 15 years of innovation in collaboration with CNS Summit, a community of innovators and life science industry leaders devoted to discovering better, more efficient ways to advance the industry through innovation, collaboration, and technology. Over the course of the series, we will feature conversations with key experts and members of the community on how the life sciences industry is continuing to reinvent itself in the pursuit of better outcomes for more patients.In this episode, guest host Dr. Alexandria Wise, SVP and Global Neuroscience Head at Syneos Health, is joined by physician-scientist Dr. Amir Kalali, Chairman and Chief Curator of CNS Summit. Dr. Kalali shares the origins of CNS Summit, the unique vision that set it apart, and the milestones achieved along the way—and offers insights on the future of collaboration in clinical development and advice for the next generation of industry leaders.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Launched in 2021 by the FDA's Oncology Center of Excellence, Project Optimus seeks to reshape traditional oncology trial designs and dosing paradigms, shifting from maximum tolerated doses to precision dosing strategies. While the FDA's hope was that the added time and cost of collecting comprehensive dose and exposure response data would benefit both patients and sponsors, there is also concern and debate in the biotech community that, if the Optimus formula is closely followed, the additional time, cost, and patient needs may, in fact, be crippling to cash-strapped emerging companies. So what is the reality around Project Optimus? And how best can it be implemented and navigated?Kicking off a new special series on Project Optimus, in this episode Nick Kenny, Chief Scientific Officer at Syneos Health, is joined by Dr. Wael Harb, Vice President on the Syneos Health Medical Oncology Team, to explore this transformative initiative, diving into the implications for biotech companies and discussing the balance between upfront investment and long-term benefits, the operational challenges of implementation, and the critical role of early planning.Stay tuned for upcoming episodes in this series, which will dive deeper into the regulatory, statistical, clinical, and operational implications of this evolving regulatory framework.For more insights from our oncology experts:Syneos Health Podcast | A Site-Specific Approach to Optimizing Diversity in Oncology TrialsWEBINAR | Transforming Oncology Drug Development: Insights from Healthcare Providers on the Frontlines of Cancer CareSyneos Health Podcast | Circulating Tumor DNA: Transforming Oncology Clinical TrialsNavigating Tumor-Agnostic Drug Development: Value, Challenges and Strategic Insights for SponsorsThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications. Syneos Health experts Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy Don Sing and Lindsay Crampton—along with Dr. Aaron Koenig, CMO of Delix Therapeutics—convened in a roundtable discussion to provide their own unique perspectives about the current and future state of psychedelic drug development and how to actively navigate the rapidly evolving field of clinical trials for these revolutionary treatments. Listen in to hear how psychedelics have progressed from their origins as a spiritual aid, their acceptance as a treatment for neuropsychiatric conditions, and the development of next-generation compounds. For more from our neuroscience experts, check out these insights: Syneos Health Podcast | Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?Artificial Intelligence and Alzheimer's: Transforming Patient Screening with Predictive ModelsWEBINAR | Psychedelics 3.0: Challenges and OpportunitiesSyneos Health Podcast | World Mental Health Day: The State of Mental Health Clinical DevelopmentBLOG | The Reimbursement Case for Psychedelic Therapies Must Incorporate the Patient's VoiceThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

As the biopharma industry strives to ensure that clinical trials reflect the rich diversity of the patient populations they aim to serve, the challenges to make this possible have fallen on the trial sites. In a recent webinar, Syneos Health experts Jane Bentley and Juliette Roberts from our Oncology Therapeutic Strategy & Innovation team, and Kelli Defenbaugh from Patient Recruitment and Retention Management, offered robust strategies and actionable insights tailored to overcome obstacles sites are facing.Listen in to learn more about how sites can contribute to enhanced diversity in oncology trials, with specific actions that sites can take to make each clinical trial better represent the population it seeks to serve.Visit here for more oncology insights from our experts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

My guest this week is Michelle Offner, Clinical Nurse Educator at Syneos Health and we discuss the evolving role of Clinical Educators for Pharma and Field Medical This weeks episode is sponsored by Syneos Health Commercial Solutions, the leading provider of the industry's broadest and most fully integrated offerings. Blending a deep understanding of human behavior and the latest technology with hard-earned knowledge and insights gained from supporting the commercialization of more products than any other partner, Syneos delivers predictive solutions that reduce risk, accelerate commercial performance, and fulfill the company's industry promise to patients. For more details, please visit syneoshealth.com   In this episode, we discuss….  Who Clinical Educators call on and who are the main external customers  Who Clinical Educators interact with internally and the main cross functional partners  How Clinical Educators work with commercial counterparts and how does it differ from MSLs  How compliance and regulatory guardrails affect Clinical Educators  and is it the same as the MSL  How Clinical Educators influence health outcomes and what value there  is to patients as well as families   The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.    MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #msltalk #careers

AI is seemingly everywhere now in our lives, including healthcare and drug discovery and development. AI certainly has the potential to enable major advances than development of more effective and safe medical products. And in fact, GenAI has already been successfully used in drug discovery. But are we fully leveraging the current AI yet in practical ways? Are our trial designs informed appropriately by AI and data? From the mundane document generation and handling to the complex patient engagement, what is the here and now of how we can and should apply AI to support more informed, more effective drug development?In this episode of the Syneos Health Podcast, Nick Kenny, Chief Scientific Officer at Syneos Health is joined by industry experts Nataraj Dasgupta, Vice President of Advanced Analytics at RxDataScience and Greg Christie, Chief Product Officer at StudyKIK to dive deep into the transformative potential of Artificial Intelligence (AI) in the realm of drug development and clinical trials. The discussion explores the practical applications of AI—from improving patient recruitment and engagement to revolutionizing document generation and protocol design—and touches on the exciting promise of Generative AI (GenAI) in streamlining processes, enhancing patient experiences, and democratizing access to clinical trials. The panel also confronts the challenges, including data accuracy, regulatory concerns, and the ethical implications of AI-driven decisions.Tune in to understand how AI is reshaping the future of healthcare and what lies ahead in this rapidly evolving field. For more AI insights from our experts:Syneos Health Podcast | Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?Artificial Intelligence and Alzheimer's: Transforming Patient Screening with Predictive ModelsSyneos Health Podcast | Turbo-Charging Clinical TrialsWEBINAR | How AI is Supercharging Clinical TrialsThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The World Economic Forum projects that by 2050, climate change could cause 14 million additional deaths and $12 trillion in global healthcare costs. And this will exacerbate global health inequities with our most vulnerable populations, including women, youth, elderly, lower-income groups, and hard-to-reach communities bearing the brunt of this change. We think we know the culprits…but do we really?The fact is, the healthcare sector is responsible for almost 5% of global greenhouse gas emissions and has a carbon footprint equivalent to 514 coal-fired power plants. And if the healthcare sector was a country, it would be the 5th largest polluter on Earth. (Source)In this episode of the Syneos Health Podcast, Nick Kenny is joined by Syneos Health colleagues Sharon Gordon, leader of our Social Impact practice and Beth Anne McPheeters, head of ESG programming, to discuss the intersection of climate change, ESG (Environmental, Social, and Governance), and healthcare.The conversation delves into the responsibilities of big industries versus collective action, the role of ESG in driving meaningful change, and the importance of integrating ESG into business goals to mitigate risks and create value, ultimately benefiting both business and patient outcomes—reinforcing that addressing climate change and promoting ESG is not just corporate responsibility but also essential for improving global health and equity.For more on how Syneos Health is committed to making purposeful actions upholding our responsibility to create a more sustainable world for each other, read our 2023 ESG Report.Check out more of our insights on the role of ESG in the healthcare industry:BLOG | Pharma Reputation Slipping, Leaving Fewer Allies in Intense EnvironmentBLOG | 4 Reasons ESG Priorities are Becoming More Important in the Life Sciences IndustryClinical Trials and Environmental, Social and Governance: Plans for Operations LeadersThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.